S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors

DISEASE CHARACTERISTICS: * Cytologically or pathologically verified cancer that is of advanced stage and for which there is no effective therapy * No lymphoma * Measurable or nonmeasurable disease * Previously irradiated (whole brain or gamma knife) brain metastases allowed provided there is no requirement for corticosteroids or anticonvulsants PATIENT CHARACTERISTICS: * Zubrod performance status 0-2 * ANC ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Hemoglobin ≥ 9 g/dL (without transfusions) * AST and ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5 times ULN if liver metastases present) * Bilirubin normal * Serum creatinine ≤ 1.5 times ULN OR measured creatinine clearance OR calculated creatinine clearance ≥ 60 mL/min * QTC interval \< 480 msec on baseline ECG OR average QTC \< 480 msec on baseline plus 2 additional screening ECG's * Fasting cholesterol \< 350 mg/dL * Fasting triglycerides \< 400 mg/dL * No uncontrolled hypertension, arterial thrombotic event, or bleeding on therapeutic anticoagulation with warfarin or heparin (including low molecular weight heparin) within the past 6 months * Able to swallow enteral medications * No feeding tubes * No intractable nausea or vomiting * No gastrointestinal (GI) tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, or uncontrolled inflammatory GI disease (e.g., Crohn, ulcerative colitis) * No history of allergic reactions attributed to compounds of similar chemical or biologic composition to rapamycin analogs (e.g., sirolimus and everolimus) * No known HIV positivity * No uncontrolled intercurrent illness including, but not limited to, the following: * Ongoing or serious active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Serious cardiac arrhythmia * History of myocardial infarction * Cerebrovascular accident within 3 months of study entry * Uncontrolled diarrhea * Psychiatric illness or social situation that would limit compliance with study requirements * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception, including barrier methods * Willing to undergo pharmacokinetic (PK) sampling and blood submission for PK and translational medicine studies PRIOR CONCURRENT THERAPY: * Recovered from all prior therapy * No prior pazopanib hydrochloride or temsirolimus * More than 28 days since prior major surgery, chemotherapy, biologic therapy, or immunotherapy * More than 28 days since prior investigational agents * At least 14 days since prior radiotherapy * No concurrent rapamycin (sirolimus) * No concurrent enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital), CYP3A4 inducers (e.g., rifampin or St. John's wort), or CYP3A4 inhibiting agents or substrates (e.g., ketoconazole, diltiazem, or verapamil) * No concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or any other type of therapy for treatment of this cancer while on this protocol * No live vaccines * Luteinizing-hormone releasing-hormone agonists allowed * Concurrent prophylactic warfarin (≤ 1 mg/day) allowed * Concurrent bisphosphonate or erythropoietin or its analogue allowed, if deemed appropriate by the treating physician